- cafead   Feb 10, 2022 at 08:12: PM
via Pfizer expects to soon reopen enrollment in a late-stage study of its experimental gene therapy for Duchenne muscular dystrophy, indicating Tuesday that a restart could be possible in the "next few months" pending regulatory feedback.
article source
article source